Alerts will be sent to your verified email
Verify EmailJBCHEPHARM
|
JB Chem & Pharma
|
Gland Pharma
|
Ajanta Pharma
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Pharmaceuticals
|
|||
|
Number of ANDA's Filed in USA
|
19.0 . | 388.0 . | 75.0 . |
|
Number of ANDA's Approved By USFDA
|
17.0 . | 337.0 . | 56.0 . |
|
Domestic Sales Growth - YoY
|
10.1 % | n/a | 7.5 % |
|
R&D as a % of Total Sales
|
1.35 % | 4.0 % | 5.0 % |
|
Financials
|
|||
|
5 yr Average ROE
|
17.95 % | 12.02 % | 21.93 % |
|
5yr average Equity Multiplier
|
1.51 | 1.15 | 1.33 |
|
5yr Average Asset Turnover Ratio
|
0.76 | 0.51 | 0.86 |
|
5yr Avg Net Profit Margin
|
15.74 % | 20.79 % | 19.12 % |
|
Price to Book
|
8.66 | 3.68 | 8.77 |
|
P/E
|
50.78 | 37.15 | 37.6 |
|
5yr Avg Cash Conversion Cycle
|
15.08 Days | 69.81 Days | -104.16 Days |
|
Inventory Days
|
50.96 Days | 118.26 Days | 45.5 Days |
|
Days Receivable
|
72.72 Days | 99.92 Days | 49.07 Days |
|
Days Payable
|
94.5 Days | 107.43 Days | 180.12 Days |
|
5yr Average Interest Coverage Ratio
|
76.53 | 183.05 | 103.83 |
|
5yr Avg ROCE
|
20.71 % | 16.55 % | 28.04 % |
|
5yr Avg Operating Profit Margin
|
24.61 % | 29.26 % | 25.85 % |
|
5 yr average Debt to Equity
|
0.07 | 0.01 | 0.01 |
|
5yr CAGR Net Profit
|
12.98 % | -6.87 % | 8.18 % |
|
5yr Average Return on Assets
|
11.91 % | 10.65 % | 16.5 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
48.8 % | 51.83 % | 66.25 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 17.94 % |
|
Change in Promoter Holding (3 Yrs)
|
-5.13 % | -6.03 % | 0.14 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
2.83 % | 11.53 % | 1.45 % |
|
JB Chem & Pharma
|
Gland Pharma
|
Ajanta Pharma
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
|
Customer Wise Break-Up
|
Customer Wise Break-Up
|
-
|
-
|
|
Asset Break-Up - Segment Wise
|
Asset Break-Up - Segment Wise
|
-
|
-
|